Clinical trial Recruiting at 1 site Interventional Ages 18 to 80

Daily peanuts for fullness, diet quality, and body composition

Official title: Dietary Peanut Intake and Nutrition-Related Outcomes in Individuals Using GLP-1 Receptor Agonists: A Randomized Controlled Trial

Run by University Hospitals Cleveland Medical Center · NCT07244458 · Data updated 2026-11-12

This study will test whether eating peanuts every day for 12 weeks helps adults taking GLP‑1 medicines feel fuller, have more energy, and improve weight and body composition.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment64 (estimated)
SponsorUniversity Hospitals Cleveland Medical Center
Academic / other
Locations1 site (Clevland, Ohio)
StatusRecruiting
StartedApril 20, 2026
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedApril 23, 2026
Trial IDNCT07244458 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with at least one weight-related comorbidity who have been taking semaglutide or tirzepatide for at least six months, are not allergic to nuts, and can attend in-person visits in Cleveland, Ohio.

Probably not a fit

People with a known nut allergy, those not using or with contraindications to GLP‑1 receptor agonists, pregnant or breastfeeding individuals, and incarcerated persons are excluded and would not receive benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study enrolls adults with obesity or overweight plus a weight-related comorbidity who have been using semaglutide or tirzepatide for at least six months. Participants will add a daily portion of peanuts to their meals for 12 weeks and undergo body composition assessment by DEXA, blood tests, and questionnaires on satiety, energy, and eating enjoyment. Investigators will track changes in weight-related outcomes, dietary quality, and selected health markers. The aim is to see if peanuts can boost fullness and overall nutrition without undermining weight management in people already on GLP‑1 receptor agonists.

Why it matters

Potential benefit: If successful, adding daily peanuts could increase satiety and improve diet quality and body composition for adults taking GLP‑1 medications.

How similar studies have gone: Previous trials of daily nut consumption have often shown improved satiety and diet quality without causing weight gain, but applying this approach specifically to people on GLP‑1 medications is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Individuals with a BMI ≥30 kg/m2 or with a BMI ≥27 kg/m2 with at least one weight-related comorbidity who have been using semaglutide or tirzepatide for a clinical indication or at least 6 months

Exclusion Criteria:

* No use or contraindication to use of a GLP-1 RA
* Known allergy to nuts
* Pregnant or breastfeeding
* Incarcerated

Where it's running

  • University Hospitals Cleveland Medical Center
    Clevland, Ohio, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.